4.915
Overview
News
Price History
Option Chain
Financials
Why BHC Down?
Discussions
Forecast
Stock Split
Dividend History
Bausch Health Companies Inc stock is traded at $4.915, with a volume of 1.45M.
It is up +2.08% in the last 24 hours and down -8.57% over the past month.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
See More
Previous Close:
$4.81
Open:
$4.87
24h Volume:
1.45M
Relative Volume:
0.70
Market Cap:
$1.84B
Revenue:
$10.53B
Net Income/Loss:
$-1.23B
P/E Ratio:
-1.5142
EPS:
-3.246
Net Cash Flow:
$949.99M
1W Performance:
-0.41%
1M Performance:
-8.57%
6M Performance:
-37.85%
1Y Performance:
-28.53%
Bausch Health Companies Inc Stock (BHC) Company Profile
Name
Bausch Health Companies Inc
Sector
Phone
514-744-6792
Address
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Compare BHC vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BHC
Bausch Health Companies Inc
|
4.915 | 1.80B | 10.53B | -1.23B | 949.99M | -3.246 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.95 | 53.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
9.84 | 42.80B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.58 | 41.09B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
75.86 | 31.62B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
558.90 | 23.23B | 3.17B | 1.29B | 1.01B | 27.09 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Aug-02-24 | Downgrade | Piper Sandler | Neutral → Underweight |
| Jul-10-24 | Initiated | Raymond James | Mkt Perform |
| Sep-20-23 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Jul-29-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-29-22 | Downgrade | Truist | Buy → Hold |
| Jul-28-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-13-22 | Resumed | JP Morgan | Overweight |
| Mar-24-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-17-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-22-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-17-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-24-20 | Initiated | Citigroup | Buy |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-22-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-02-19 | Initiated | Goldman | Neutral |
| Oct-25-19 | Initiated | Cowen | Outperform |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Aug-15-19 | Upgrade | TD Securities | Hold → Buy |
| Jul-19-19 | Initiated | Wolfe Research | Outperform |
| Jun-11-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Jan-02-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Nov-05-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-18 | Upgrade | Piper Jaffray | Underweight → Neutral |
View All
Bausch Health Companies Inc Stock (BHC) Latest News
Bausch Health plans July 29 call for Q2 results and business update - Stock Titan
Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026 - TradingView
Bausch Health Continues Specialty Pharma Strategy In 6 July 2026 - Kalkine Media
Why Did Bausch Health (TSX:BHC) Announce a Board Change? - Kalkine Media
Québec is the first province to list (Pr)OKEDI(MC) (extended-release injectable suspension of risperidone) on the public drug reimbursement formulary for the treatment of schizophrenia - Yahoo! Finance Canada
Bausch Health Companies (BHC) Posts Modest Gain, Tests Resistance ZoneETF AUM Growth - dars.gov.et
Bausch Health (BHC) director granted RSUs in lieu of cash fees - Stock Titan
Bausch Health (NYSE: BHC) director John Paulson granted 12,677 RSUs as board pay - Stock Titan
Bausch Health (NYSE: BHC) director granted 6,845 RSUs as board compensation - Stock Titan
Bausch Health (TSX:BHC) Board Change Follows Director Resignation - Kalkine Media
Best TSX Healthcare Stocks to Watch for July 2026 - Kalkine Media
Michael Goettler Resigns from Bausch Health's Board of Directors - The Globe and Mail
Director Michael Goettler exits Bausch Health (NYSE: BHC) board - Stock Titan
Bausch + Lomb survey finds dry eye affects emotional health By Investing.com - Investing.com South Africa
Why Is Bausch Health (TSX:BHC) Expanding Beyond the S&P/TSX? - Kalkine Media
BVF Forecast — Price Target — Prediction for 2027 - TradingView
Bausch Health (BHC) Drops Nearly 10%: Support Levels in Focus After Sharp DeclineMean Reversion Trade - dars.gov.et
Bausch Health Companies Inc. Actuals & Estimates (TSX:BHC) - TradingView
Bausch Health Companies Inc. Actuals & Estimates (TRADEGATE:BVF) - TradingView
Bausch Health Companies Inc. Actuals & Estimates (MUN:BVF) - TradingView
Price to earnings forward of Bausch Health Companies Inc. – FWB:BVF - TradingView
Bausch Health Companies Inc. Actuals & Estimates (NYSE:BHC) - TradingView
Bausch Health Companies Inc. Actuals & Estimates (FWB:BVF) - TradingView
Bausch Health Companies Inc. Actuals & Estimates (BOATS:BHC) - TradingView
Bausch Health Companies Inc. Actuals & Estimates (LSX:A2JQ1X) - TradingView
Bausch Health Companies Inc. Actuals & Estimates (BIVA:BHC/N) - TradingView
BHC Forecast — Price Target — Prediction for 2027 - TradingView
Bausch Health Companies adjusts debt profile, shares react to refinancing step - AD HOC NEWS
Price to earnings forward of Bausch Health Companies Inc. – BOATS:BHC - TradingView
Bausch Health Companies Inc (BHC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biotrue Hydration Boost Rehydrating Contact Lens Drops from Bausch Health Companiesquiet comfort - Ad-hoc-news.de
Can Bausch Health (TSX:BHC) Drive TSX Healthcare Stocks Higher? - Kalkine Media
Why Is Bausch Health (TSX:BHC) Expanding Its S&P/TSX Composite Footprint? - Kalkine Media
Bausch Health Cos (BHC) Institutional Ownership 2026 $BHC - MarketBeat
Bausch Health Companies Inc (BHC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bausch Health Companies Inc (BHC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bausch Health Companies Inc - TradingKey
Bausch Health’s Debt Strategy Shapes Its Market Narrative - Kalkine Media
Bausch Health Companies Inc (BHC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bausch Health Companies Inc (BHC) Institutional Confidence - TradingKey
Bausch Health Companies Inc (BHC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bausch Health Companies Inc (BHC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bausch Health Companies Inc (BHC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bausch Health stock hits 52-week low at 4.91 USD By Investing.com - Investing.com South Africa
Bausch Health stock hits 52-week low at 4.91 USD - Investing.com
Actinic Keratosis Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Almirall, Biofrontera Pharma, Vidac Pharma, Rubedo Life Sciences, Bausch Health, Sandoz Pharma - Barchart.com
TSX Healthcare Stocks: Which Names Are Drawing Market Attention? - Kalkine Media
BHC Q1 2026 Earnings: EPS Surges 12.33% Above Estimates, Shares Edge HigherEarnings Surprise Score - newsline.com
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of (Pr)OKEDI® (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia - Cantech Letter
Why Bausch Health Companies Inc stock is sliding today - Wealth Awesome
Barclays Maintains Bausch Health(BHC.US) With Hold Rating, Maintains Target Price $7 - Moomoo
Bausch Health Companies Inc Stock (BHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):